A retrospective study comparing expandable metal stenting with radiation therapy in advanced oesophageal carcinoma  in a regional South African hospital by Liakos, Dimitri
 1
A RETROSPECTIVE STUDY COMPARING EXPANDABLE 
METAL STENTING WITH RADIATION THERAPY IN 
ADVANCED OESOPHAGEAL CARCINOMA IN A REGIONAL 
SOUTH AFRICAN HOSPITAL 
 
 
 
 
 
Dimitri Liakos 
 
 
 
 
 
 
A research report submitted to the Faculty of Medicine, University of the 
Witwatersrand, in partial fulfillment of the requirements for the Degree of 
Master of Medicine in the division of General Surgery. 
 
Johannesburg 2012 
 
 
 2
DECLARATION 
 
I, Dimitri Liakos, declare that the contents of the paper are all work of the author.  
It’s being submitted for the degree of Master of Medicine, in the division of 
General Surgery, at the University of the Witwatersrand, Johannesburg.  It has 
not been submitted before for any degree or examination at this or any other 
university. 
 
This research report is based on this work, which has been published in the 
South African Journal of Surgery. 
 
• Liakos D, Dower DWR, Florizoone M, Bizos, DB.  Is oesophageal stenting 
for cancer the answer? A report from a secondary hospital in the 
developing world.  SAfr J Surg. 2010; 48:43-49. 
 
 
 
 
………………………………………… 
Nineteenth day of April 2012 
 
 
 
 
 
 
 
 
 3
LETTER SIGNED BY CO-AUTHORS 
 
 
 
 
 
 4
CONGRESS PRESENTATIONS ARISING FROM STUDY 
 
Liakos D, Dower DWR, Florizoone M, Bizos, DB.  Is oesophageal stenting the 
answer? A report from a secondary hospital in the developing world.  SAfr J 
Surg. 2010; 48:43-49 (Appendix A). 
 
• Presented to the Bert Myburgh Surgical Symposium in November 2008, 
Johannesburg, South Africa. 
 
• Presented to the Surgical Research Society of Southern Africa in June 
2009, Johannesburg, South Africa. 
 
• Poster presentation to the Faculty of Health Sciences Research Day, 
University of the Witwatersrand in August 2008, Johannesburg, South 
Africa (Appendix B). 
 
 
 
 
 
 
 
 
 
 
 
 
 5
ABSTRACT 
 
 
Introduction   
Oesophageal cancer causes much morbidity and mortality in South Africa.  
This disease has a 5-year survival of less than 10% despite improvements in 
therapy.  Most patients present with advanced disease and are suitable only for 
palliative care.  Current standard of palliative care for patients with end-stage 
oesophageal cancer that present with dysphagia include brachytherapy and 
stenting.  Brachytherapy improves survival and has a more stable quality of life 
in the long term when compared to stenting.  Conversely stenting has a more 
acute relief of dysphagia.    In South Africa many patients with malignant 
dysphagia face socio-economic constraints that cause delays in therapy, 
especially in patients from rural areas. 
Many prospective randomized trials of palliative treatment have been done in 
the developed world, not taking into account socio-economic constraints.  We 
present a study from Tshepong Hospital (Klerksdorp, North West province), a 
secondary hospital in South Africa. 
The aim of the dissertation was to compare radiation therapy versus stenting for 
the palliative treatment of advanced oesophageal cancer with malignant 
dysphagia in the South African context, especially looking at the impact of socio-
economic constraints on patient management. 
Patients and methods 
We retrospectively reviewed the data on 30 patients seen between February 
2005 and January 2008. All patients presented with inoperable oesophageal 
cancer and were palliated with either radiotherapy (N=12) or stenting (N=18). 
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Due to delays in treatment with radiotherapy, stenting was introduced in the 
unit as an alternative treatment option.  Radiotherapy included either external 
beam radiotherapy or brachytherapy.  We compared the number of admissions, 
length of hospital stay and time from when first seen to intervention as primary 
outcomes. 
Results 
Patients presented with either grade III or IV dysphagia.  The median age was 64 
in the stent group and 72 in the radiotherapy group.  The majority of patients 
were male in both groups.  All patients had confirmed squamous cell carcinoma.  
The number of admissions, length of hospital stay and days to procedure were 
significantly lower in the stent group (p=0.018, p=0.0072 and p=0.0108 
respectively).  The time before intervention was 6 days in the stent group versus 
49 in the radiation therapy group. No major complications as a result of 
brachytherapy were reported. Conversely, complications in the stent group 
included chest pain, tumour overgrowth, stent migration and death. 
Conclusion 
Patients with malignant dysphagia have a limited lifespan and focus should be on 
improving the quality of life in these patients.  Patients undergoing radiotherapy 
have a significantly longer hospital stay and longer wait to treatment.  With 
socio-economic constraints imposed upon the health sectors of the developing 
world, we conclude that stenting is a feasible option in this situation.  Adopting a 
prognostic score might help in identifying patients with a poor prognosis.    
Either the situation should be improved or stenting should become the preferred 
treatment. 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
Seventy years ago oesophageal squamous cell carcinoma (OSCC) was a rare 
disease in the South African population  (1).  It has become endemic in some 
rural areas of South Africa like the Transkei, posing a major health concern  (2). 
This devastating disease has a 5-year survival of less than 10% despite 
improvements in therapy  (3). Due to advanced disease at presentation, over 
50% of patients are only suitable for palliative care  (4), and due to the advanced 
stage of disease there is no prospect for cure  (5).   
Patients with advanced disease usually present with dysphagia and the primary 
goal is to alleviate the dysphagia quickly, permanently and with minimal 
morbidity with the aim of restoring some quality of life to the patient.  Common 
palliative treatment modalities include placement of expandable metal stents 
and radiation therapy (RT).  Many clinical trials  (6,7) (8) comparing the 
treatment modalities of palliative therapy have been done in First World 
countries and their outcomes may not be applicable in a developing country due 
to socio-economic constraints. 
During this study, most patients with malignant dysphagia seen at our hospital 
(Tshepong Hospital, Klerksdorp, North West, South Africa) were from distant 
rural areas and needed to be referred to tertiary centers for RT (external beam 
RT or brachytherapy).  A number of problems were encountered during the 
referral of these patients, including logistic delays, resource constraints and poor 
follow-up, which led to prolonged hospital stays and increased morbidities.   
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This led to the introduction of stenting as an alternative option for these patients 
seen at our institution, thereby reducing hospital stays.  The following literature 
review focuses on OSCC and the palliative therapy thereof. 
 
1.1. INCIDENCE AND DEMOGRAPHICS 
 
Oesophageal cancer is the eighth most common cancer worldwide, with OSCC 
being the most prevalent  (9).  In contrast to oesophageal adenocarcinoma 
(OAC), which is more common in Western countries, OSCC predominates in 
developing countries  (9).  
South Africa has some of the highest reported cases of OSCC in the world, with 
incidences reaching 100/100000 cases per year  (10).   
In black South Africans it is the second most common cancer in males and the 
forth most common cancer in females.  In the black male population it comprises 
13 % of all cancers reported  (11).  Furthermore  (3), there is a three- to four-fold 
increased risk in males compared to females for developing OSCC.  The most 
prevalent age group for the development of oesophageal cancer is above 40, 
beyond which the incidence rises after each decade.  
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1.2. PATHOPHYSIOLOGY AND RISK FACTORS 
 
Although the etiology of OSCC is unknown, there is a strong association with 
alcohol consumption and smoking  (12).  The risk of OSCC increases with the 
dose and duration of tobacco smoking  (13); patients who smoked more than 20 
cigarettes for more than 35 years had an odds ratio of 10.4 of developing OSCC.  
The latter study also described an increased risk if heavy alcohol consumption 
was combined with tobacco smoking.  A snuff preparation of tobacco did not 
have a statistical increase in the risk for OSCC.  Heavy alcohol consumption  (12), 
of more than 3 drinks per day, has been shown to be independently and 
significantly associated with an increased risk of developing OSCC.  
In contrast to the strong association of tobacco smoking with OSCC, this was not 
a strong risk factor for OAC and neither was alcohol consumption  (13).  
 
Nutritional deficiencies  (3) may also play a role in the development of OSCC.   
These deficiencies include vitamins A and -C and zinc. Generally these 
deficiencies are associated with diets rich in carbohydrates and low in proteins 
and green vegetables.  The commonly consumed diet in rural areas, such as the 
Transkei, comprises mostly of the staple cereal, maize, which represents such a 
diet.  
There has been controversy about an association between achalasia of the 
oesophagus and an increased risk of OSCC.  Streitz’s group  (14) described an 
increased risk of 14.5 times for the development of OSCC in patients with 
achalasia when compared to an age-adjusted and sex-adjusted control 
population. 
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Other conditions that have been associated with OSCC include tylosis  (15), a 
rare autosomal dominant condition of abnormal keratinisation, Plummer-Vinson 
syndrome, Zenker’s diverticulum of the pharyngo-eosophagus and previous 
radiation exposure to the oesophagus.   
According to the literature  (16,17), the major risk factors for the development of 
OAC are gastro-oesophageal reflux disease (GORD) and Barret’s oesophagus.  A 
study by Lagergen et al  (18) showed that a high BMI (>30kg/m2) was also 
associated with OAC, but not with OSCC. 
 
OSCC is usually located in the middle third of the oesophagus compared to OAC 
in which the lower third may invade the gastric cardia.  Early lesions of OSCC 
appear small and grey-white with plaque thickenings which may become raised 
or ulcerate.  They eventually become large tumorous masses that may encircle 
the whole lumen of the oesophagus and eventually occlude it.  Most OSCCs are 
moderately to well differentiated.  Histological variants include verrucous 
carcinoma and carcinosarcoma (spindle cell carcinoma)  (19). 
Molecular genetics also play a role in the development of OSCC and OAC.  The 
p53 gene, which is required for normal cell apoptosis, was associated with 
mutations in both OSCC and OAC that result in continued cell growth  (15).  Also, 
there has been much interest in the over-expression of certain growth factors  
(20), like epidermal growth factor (EGF) and transforming growth factor beta 
(TGFß), in OSCC.  It was suggested that EGF interferes with the effects of the 
adhesion molecule, E-cadherin, and thereby changes the behaviour of the 
squamous cell to a more aggressive phenotype with increased invasive 
properties. 
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1.3. INVESTIGATIONS AND STAGING 
 
On presentation all patients suspected of having oesophageal cancer should have 
a thorough clinical examination, history taking and medical fitness assessment 
for a surgical procedure, chemotherapy, RT or a combination of treatments.  
Patients should undergo routine blood and radiological investigations (chest 
radiograph).  A contrast swallow may also be performed before endoscopy  (21) 
with the rationale that a barium swallow radiograph can reveal any contour and 
motility abnormalities such as strictures and achalasia, and exclude the presence 
of airway fistulas.    
Endoscopy should be performed and a histological diagnosis of malignancy 
confirmed.  The staging of oesophageal cancer should include depth of local 
invasion, regional lymph node involvement and presence of metastatic disease. 
Staging is important for the appropriate management of patients. Patients with 
oesophageal cancer should be staged according to the TNM classification 
developed by the American Joint Committee on Cancer  (22), as shown in Table 
Ia, Ib and Ic.   
 
Computed tomography (CT) is the initial investigation of choice  (23) for 
determining if the patient has a resectable tumor and whether lymph node or 
distal metastasis is present.  According to the literature, endoscopic ultrasound 
(EUS) is useful for determining the depth of invasion of the tumor and the 
presence of loco-regional lymph node involvement.  EUS  (24) is also able to 
determine lymph node involvement reasonably accurately using size and 
morphology of lymph nodes.   
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Ultrasonographic features, which suggest malignant lymphadenopathy, include 
lymph nodes that are homogeneous, hypoechoic (dark), rounded as opposed to 
elliptical, have well demarcated borders and are larger than 10 millimeters.  EUS 
has a sensitivity of 89.1% and a specificity of 75% in predicting the presence of 
malignant lymph nodes.  Furthermore  (25) the size and proximity of lymph 
nodes to the primary tumor also predicted the presence of malignant lymph 
nodes.    When fine needle aspiration (FNA) is combined with EUS (EUS-FNA), 
the accuracy of determining lymph node involvement is increased  (26,27). 
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Table Ia.  TNM Classification for Oesophageal Cancer  
(2010 American Joint Committee on Cancer) 
Category Description 
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis High-grade dysplasia (HGD) 
T1 Tumors invade lamina propria, muscularis mucosae, or submucosa 
T1a Tumor invades lamina propria or muscularis mucosae 
T1b Tumor invades submucosa 
T2 Tumors invade muscularis propria 
T3 Tumors invaded adventitia 
T4 Tumors invade adjacent structures 
T4a Resectable tumor invading pleura, pericardium, or diaphragm 
T4b Unresectable tumor invading other adjacent structures, such as aorta, 
vertebral body, trachea, etc. 
Regional Lymph Nodes (N) 
NX Lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 lymph nodes 
N2 Metastasis in 3-6 lymph nodes 
N3 Metastasis in seven or more regional lymph nodes 
 
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant Metastasis 
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Table Ib. Histologic Grade (G) of Oesophageal Cancer 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 
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IV Any Any M1 Any Any 
*Location of the primary cancer site is defined by the position of the upper (proximal) edge 
of the tumor in the oesophagus. 
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer-
Verlag New York, www.springer.com  (22). 
 
 
Table Ic. 
Anatomic Stage/Prognostic Groups for Squamous Cell Carcinoma  
 
Stage T N M Grade Tumor 
location* 
0 Tis (HGD) N0 M0 1, X Any 
IA T1 NO MO 1, X Any 
IB T1 N0 M0 2-3 Any 
 T2-3 N0 M0 1, X Lower, X 
IIA T2-3 N0 M0 1, X Upper, 
Middle 
 T2-3 N0 M0 2-3 Lower, X 
IIB T2-3 N0 M0 2-3 Upper, 
Middle 
 T1-2 N1 M0 Any Any 
IIIA T1-2 N2 M0 Any Any 
 T3 N1 M0 Any Any 
 T4a N0 M0 Any Any 
IIIB T3 N2 M0 Any Any 
IIIC T4a N1-2 M0 Any Any 
 T4b Any M0 Any Any 
 Any N3 M0 Any Any 
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In a study conducted by the Mayo clinic, comparing spiral CT, EUS and EUS-FNA  
(28) for the lymph node staging of patients with oesophageal cancer, the results 
showed increased sensitivity of EUS-FNA when staging lymph node involvement 
compared to the other modalities.  Furthermore  (28), EUS-FNA results altered 
the management plan in 77% of patients and significantly altered therapy by 
correcting the CT-tumor stage.   
Concerns when using EUS as a modality is the risk of perforation  (29) in patients 
that present with malignant dysphagia, and therefore these patients would have 
to undergo serial dilatations of the oesophagus before intervention.  Thin EUS 
probes that can be passed through the endoscope can overcome the risk of 
perforation.   
Also, patients that presented with malignant dysphagia had a high probability of 
having advanced (stage III/IV) disease. 
 
1.4. TREATMENT MODALITIES 
 
1.4.1. Curative therapy 
 
Stage I-III can be assumed to be resectable disease.  Surgery is the mainstay 
of treatment for resectable disease. Perioperative chemotherapy 
substantially improved survival  (30), and a combination of chemotherapy 
with RT followed by surgery resulted in higher median survival times  (31). 
Neo-adjuvant chemoradiotherapy (CRT)  (32) is now the mainstay of 
treatment for resectable oesophageal tumors. 
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1.4.2. Palliative therapy 
 
1.4.2.1. Selection of patients for palliative therapy 
 
After careful staging of the disease, patients’ fitness for treatment should be 
assessed.  In general, patients who are not fit enough for surgery will not be 
fit enough for radical RT or chemotherapy  (15).  Treatment options should 
be discussed with the patient and psychological well-being should be 
addressed.   
Once all these issues have been resolved the palliative treatment of choice 
should be offered to the patient.  It should be noted that the median survival 
in patients with advanced disease is poor at 120 days  (33).  
 
1.4.2.2. Mechanical endoscopic methods for relieving obstruction 
 
Mechanical methods for relieving obstruction include dilatation only and 
dilatation followed by stenting of the oesophagus.   
Intubation of the oesophagus for the treatment of malignant strictures of the 
oesophagus has been described as early as 1887  (34).   Advances of 
oesophageal intubation saw the Celestin tube (plastic tube) being introduced 
as palliative therapy for malignant dysphagia  (35); the insertion of this tube, 
however, required laparotomy for insertion and had many complications, 
including high perforation rate, hemorrhage and need for gastrostomy.   
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In 1980 Procter  (36) described the advantages of the Procter-Livingstone 
tube, which did not require a laparotomy and, due to its shorter length, did 
not cause erosions and bleeding of the gastric mucosa.   
Plastic stents, although they provide quick, inexpensive and long-term 
palliation in patients with malignant dysphagia, are not without 
complications.  Procedure-related complications include oesophageal 
perforation, bleeding, pain and dislodgement post intubation.   
In 1973 Didcott  (37) described the Didcott Dilator (a metal stent), which was 
used for the slow dilatation of the oesophagus due to benign strictures.  This 
dilator was the forerunner to the current self-expandable metal stent (SEMS). 
The mortality rate associated with the intubation of plastic stents may be as 
high as 8%  (38) (39) and in a prospective study comparing plastic stents to 
SEMS, plastic stent insertion was associated with higher complications and 
mortality rates.  Although perforation and bleeding are also complications of 
SEMS, they occur at a lower rate compared to plastic stents. Other 
complications in the SEMS group included tumor in-growth and lumen 
obstruction by impacted food causing recurrent dysphagia and reflux 
oesophagitis.  The median survival time  (38), however, was equal between 
the two (De Palma 1996).  These findings were similar to those reported by  
(40).  Conversely, O’Donnell  (41) found an increase in survival in the SEMS 
group, with a median survival in the SEMS group of 102 days versus 62 days 
in the plastic stent group.   
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SEMS are effective, easy to use, and have fewer complications and lower 
mortality rates compared to plastic stents.  SEMS seem to be the preferred 
choice over plastic stents.   However, the costs of SEMS are substantially 
more than plastic stents. A group from Natal  (42), South Africa, compared 
plastic stents to SEMS and investigated the cost-effectiveness of SEMS.  They 
reported that the cost of the stent, including hospital stay, amounted to R 
4123 in the SEMS group versus R 2146 in the plastic endoprosthesis group, 
making the SEMS group 1.9 times more expensive.  Nevertheless, the clear 
advantages of SEMS constitute them the mainstay of stent therapy in 
malignant dysphagia. 
 
The initial, so-called first generation SEMS were uncoated, but concerns of 
recurrent dysphagia, due to tumor in-growth and lumen obstruction with 
impacted food, prompted the use of coated metal stents to be introduced.  
The rates of recurrent dysphagia were found to be less in a prospective study 
when coated metal stents were used compared to uncoated metal stents  
(43).  Completely covered metal stents, however, had an unacceptably high 
rate of migration due to the inability of the stent to integrate into the wall of 
the oesophagus  (44).  The development of a so-called second generation, 
partially covered SEMS had more promising results subsequently  (45).   
A few years later, a randomized, controlled trial  (46) compared partially-
covered SEMS to uncovered-SEMS and found that 27% of the patients in the 
uncovered stent group needed re-intervention due to tumor in-growth, as 
opposed to none of the patients in the partially-covered stent group.  
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This difference was found to be statistically significant.  Food impaction 
causing obstruction was seen more frequently in the uncovered stent group 
whereas stent migration was more frequent in the partially-covered stent 
group; both these outcomes did not reach statistical significance. 
Therefore while uncovered stents have less chance of migrating, the chance 
of obstruction due to tumor in-growth and/or food impaction is higher when 
compared to covered stents. The partially covered stent has the proximal and 
distal edges exposed to allow for mucosal in-growth, which prevents stent 
migration (a problem with the completely covered SEMS).   
The remaining bulk of the stent is covered to prevent tumor in-growth. Two 
commonly used second generation SEMS, the Flamingo Wallstent (Boston 
Scientific, Natrick, MA, USA) and the Ultraflex stent (Boston Scientific, 
Natrick, MA, USA) were compared by Sabharwal  (47), looking at dysphagia 
scores, migration of stent, severe reflux and other complications.  Outcomes 
were similar between the 2 groups and the authors state the Flamingo 
Wallstent however allows more accurate placement.  Two patients with the 
Ultraflex stent presented with stent migration compared to one patient with 
a Wallstent.  
Furthermore, a prospective trial involving 100 patients  (48) compared the 
Ultraflex stent, the Flamingo Wallstent, and the covered Z-stent (Wilson-Cokk 
Medical, Winston-Salem, NC, USA).  There were no significant differences in 
the improvement of dysphagia or the recurrence of dysphagia or 
complication rates between the 3 different covered metal stents. 
If the SEMS are placed across the gastro-oesophageal junction, gastro-
oesophageal reflux becomes problematic.  Reflux may also cause dyspnoea 
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due to micro-aspiration of gastric contents, which occurs especially at night.  
An attempt to overcome this complication was the development of the anti-
reflux stent.  
SEMS with a dual anti-reflux valve (Wilson Cook Medical, Winston-Salem, 
North Carolina) was compared to a standard SEMS with no difference in 
complications, dysphagia score, survival and global health score  (49).  Reflux 
symptoms were also not improved with the use of the anti-reflux stent but 
some improvement was seen with dyspnoeic symptoms.  Of note is that 
assessment of reflux in the preceding study was based on symptoms alone.  
A more scientific approach was used to assess the effectiveness of an anti-
reflux valve by 24-hour pH monitoring in a study by Homs   (50).  They 
reported no decrease in reflux or acidic environment with the use of the anti-
reflex valve in SEMS.   
Furthermore, anti-reflux stents are not effective against preventing reflux but 
may reduce symptoms of dyspnoea.   
In a meta-analysis by Sgourakis   (51), looking at 16 randomised controlled trials 
comparing different SEMS to each other and SEMS to loco-regional palliative 
treatment modalities.  These loco-regional treatment modalities included laser, 
thermal ablation, radiation therapy and argon plasma coagulation.  They found no 
superiority of anti-reflux stents over standard SEMS.  Furthermore the Flamingo 
stent had a better overall dysphagia score at 4 weeks and the Ultraflex stent was 
found to be the most inferior with regard to bolus occlusion. 
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Analysis of the current data reveals minor differences exist between the 
different types of SEMS available for use and choice should be dependant on 
tumor location, anatomy and cost.   
 
1.4.2.3. Non-mechanical endoscopic methods for relieving obstruction 
 
Other methods have been described for the palliation of malignant dysphagia, 
including thermal ablation using laser therapy, photodynamic therapy (PDT) 
and injecting of the tumor with sclerosants like ethyl alcohol.   
Laser therapy uses neodynium ytrium aluminium garnet laser (Nd:YAG) to 
ablate the tumor and PDT involves injecting the tumor with porfimer sodium 
and then treatment with red light of 630nm wavelength  (52). 
Complications of laser therapy include pain, perforation, bleeding, repeated 
hospital admissions due to tumor overgrowth and fibrotic strictures.  
Complications of PDT include photosensitivity that may last up to 6 weeks 
after treatment, perforation, fistula formation and oesophagitis causing pain 
and fibrosis  (15). 
A large, multicenter, randomized trial was performed comparing PDT to laser 
therapy  (52).  Both modes of therapy had an average palliation failure time 
of 1 month and a quarter of the patients in both groups had no change in the 
dysphagia score after therapy.  PDT had more adverse effects than laser 
therapy, which included sunburn, nausea, fever and asymptomatic pleural 
effusions.  On the other hand laser therapy had more severe adverse affects 
which included a 7% perforation rate compared to 1% in the PDT group .   
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In a smaller study, the durability of palliation was longer at 84 days in the 
PDT group compared to 57 days in the laser group, p=0.008  (53). 
Furthermore laser therapy was not effective in long tumors, or very narrow 
tumors or where tumors were not exophytic  (54) (55).   
Although there are benefits of laser therapy in rapid alleviation of dysphagia 
in patients with advanced oesophageal cancer, the main problem with laser 
therapy is the need for repeat sessions every 4-6 weeks to maintain patency 
of the oesophagus.  Sargeant  (56) looked at combining laser therapy with 
external beam RT (30 Gy in 10 fraction) to reduce the frequency of laser 
treatments.  Time to laser was increased from 5 weeks to 9 weeks, but with a 
higher complication rate in patients being exposed to RT.  These patients 
developed oesophageal strictures and had a higher rate of perforations and 
fistulae formations.   
In a randomized study by Spencer  (57), laser therapy was combined with 
brachytherapy and compared to laser therapy alone.  Brachytherapy was give 
as a single fraction.  There was a statistically significant difference with 
regard to mean time to recurrence of dysphagia in favour of the 
laser/brachytherapy combination group. 
In the laser therapy alone group time to recurrence was 5 weeks whereas in 
the bracytherapy and laser therapy combination group the mean time to 
recurrence was 19 weeks.  There was no difference in the mean survival time 
between the 2 groups.  The median survival was 20 weeks in the laser alone 
group and 26 weeks in the combination treatment group.  
In a small clinical trial laser therapy was compared to brachytherapy as sole 
modality treatment options  (58).   
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Laser therapy versus brachytherapy confirmed that brachytherapy had a 
better long-term patency of palliative therapy than laser therapy however 
initial relief of dysphagia was slightly better in the laser group.    
When laser therapy was compared to SEMS in a randomized trial  (59), it was 
found that the relief of dysphagia (which was poor in both groups) was 
similar in both groups but the laser group had a higher survival time of 125 
days compared to 68 days in the SEMS group.  The authors did mention that 
the population group included old, frail patients with co-morbidities.  
Recurrent dysphagia was also higher in the laser group, 7 patients compared 
to 4 in the SEMS group.  The authors also described a longer hospital stay and 
cost in the laser group.   
In contrast to the above study, Adam  (60) found a better initial relief of 
dysphagia when using SEMS compared to laser ablation therapy.  
Conflicting results exist between laser therapy and SEMS.  Initial relief of 
dysphagia seems to be similar between the 2 groups but with an increased 
rate of tumor recurrence in the laser group. 
Endoluminal YAG-laser ablation therapy is a feasible option for the palliation 
of malignant dysphagia however, its durability is its shortfall with 
combination RT needed to extend the duration of palliation and an 
experienced endoscopist with laser therapy is needed   (61). 
PDT although has a longer durability, is easier to perform and has a lower 
perforation rate than laser therapy, its costly and has excessive adverse 
effects to patients.  
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New advances in metallic stent technology render them safe and simple to 
use with less adverse effects than laser therapy or PDT with shorter hospital 
stay  (61), however complications of stent migration and hemorrhage can be 
problematic  (62).  In addition, results have shown that the use of SEMS after 
radiation and/or chemotherapy is safe, but with an increased risk of 
retrosternal pain  (63). 
Despite reports of effective results comparable to laser therapy with the use 
of ethyl alcohol injections  (15) to induce chemical necrosis of the tumor with 
the aim of relieving dysphagia, it comes with considerably more pain.  The 
use of ethanol injections has not become widespread. 
 
1.4.2.4. Radiation therapy and chemoradiotherapy 
 
RT includes both external beam RT (EBRT) and intra-luminal brachytherapy.  
EBRT requires considerably more therapy sessions with higher 
complications than brachytherapy due to the damaging of normal 
surrounding tissue.   
Work has been done on EBRT as palliative treatment in malignant dysphagia.  
Complications of RT include oesophagitis, ulcerations of the oesophagus, 
fistula formation and hemorrhage  (15). 
The role of EBRT in malignant dysphagia is to shrink the tumor enough to 
allow for intra-luminal brachytherapy to be delivered, and not as a sole 
modality for palliative therapy  (64).  When EBRT was compared to 
brachytherapy, it was clear that brachytherapy was a better option for 
palliative therapy than ERBT alone  (65). 
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Brachytherapy was first used as a booster to EBRT with promising results  
(66).  Brachytherapy delivers high doses of RT to the lumen of the 
oesophagus with rapid shrinkage of the tumor.  One of the main 
complications is the formation of strictures after treatment.  These strictures 
were successfully managed with the Didcott Dilator.  
Brachytherapy can be given in different doses and much work has been done 
looking at which is the most effective dose with the least morbidity by Sur in 
South Africa.  In a small study  (67) different doses of high dose rate (HDR) 
brachytherapy were compared.  It was a small study with 25 patients.  The 
authors concluded that 12-15 Gy given as a single fraction, was effectively the 
best dose for the relief of dysphagia with the least   morbidity; this however 
was just a preliminary report. 
A larger study  (68) looked at 172 patients, divided into 3 groups.  The groups 
received different doses of HDR brachytherapy, 12Gy/2 fractions, 16 Gy/2 
fractions and 18 Gy/3 fractions.  The fractions were given on a weekly basis.  
Patients that received the highest dose of HDR brachytherapy (16 Gy/2 
fractions and 18 Gy/3 fractions) had the longest median survival and the 
longest dysphagia free survival. 
Sur  (69) then followed up with a large, prospective, randomized trial that 
involved 232 patients.  All patients were diagnosed with OSCC.  Patients were 
divided into 2 treatment arms, delivery of HDR brachytherapy at 16Gy in 2 
fractions  (group A) or 18Gy in 3 fractions (group B).  
 Statistically there were no differences between the 2 treatment groups 
regarding all outcomes and the dysphagia-free survival was 7.8 months in 
group A and 6.3 months in group B.   
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Overall survival in both groups was 7.9 months.  Stricture rates were 10.7% 
versus 10.8% in groups A and B respectively.  Fistula rates were also similar 
at 9.8% and 10% respectively.   
Homs  (70) reported less impressive results with the use of single-dose HDR 
brachytherapy.  In their retrospective study 137 (92%) patients received 15 
Gy in a single fraction but the dysphagia score improved in only 51% of their 
patients, and after 6 weeks the mean dysphagia improved from a score of 3 to 
2.  Mean survival was 160 days and 34/149 patients required stenting for 
persistent dysphagia.   
Brachytherapy and SEMS placement are the most widely used forms of 
palliation for malignant dysphagia.  The SIREC study  (6) (a large, Dutch, 
multicenter, randomized trial) compared single-dose brachytherapy to stent 
placement primarily looking at dysphagia relief, median survival and quality 
of life scores.   
Single-dose brachytherapy (12 Gy as a single fraction) had a better dysphagia 
score at 30 days than the stent group but the initial relief of dysphagia was 
better in the stent group.  Furthermore the brachytherapy group had more 
days with almost no dysphagia (grade 0 or 1, Table II)  (71) at 115 days 
versus 82 days in the stent group.  Overall median survival was also slightly 
longer in the brachytherapy group at 155 days versus 145 days in the stent 
group and a better quality of life score was seen in the brachytherapy group. 
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Table II. Degree of dysphagia in patients with inoperable 
carcinoma of the oesophagus  
Symptom Degree of dysphagia 
No dysphagia 0 
Dysphagia for solids I 
Dysphagia for semi-solids II 
Dysphagia for liquids III 
Complete dysphagia IV 
 
 
A further look into the health-related quality of life scores (HRQoL) revealed 
that initial scores were stable in both the brachytherapy and stent groups, 
however on 3-month follow-up there was deterioration in both groups but 
more so in the stent group  (72). 
Another randomized, controlled trial  (33) from the Netherlands comparing 
stenting to brachytherapy revealed that stenting provided a more instant 
relief of dysphagia over brachytherapy, however brachythearpy offered a 
more stable HRQoL in the long run.  Quality of health scores are calculated 
based on physical, emotional, social, cognitive and functioning of the patient.  
Overall median survival was comparable in both groups (around 120 days).   
Brachytherapy was given as 7 Gy in 3 fractions in contrast to a single dose of 
12 Gy in the SIREC study  (6). 
Wenger  (73) randomized 30 patients to receive 7Gy in 3 fractions of 
brachytherapy and 30 patients into the stent group.  
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The results in the study compared to other studies.  After 1 month dysphagia 
scores were better in the stent group but after 3 months dysphagia scores 
were better in the brachytherapy group.  Additionally 8 patients in the stent 
group required intervention in a median 83 days and in the brachytherapy 
group seven patients required intervention in a median 225 days due to 
progressive tumor overgrowth.  Interestingly, the patients in the 
brachytherapy group that required re-intervention were stented.  Median 
survival was similar in both groups at 158 days in the stent group and 162 
days in the brachytherapy group. 
Brachytherapy whether given in a single fraction or higher doses in 2 or 3 
fractions provides longer relief of dysphagia compared to stenting and 
provides a longer median survival in advanced cancer of the oesophagus. 
In the meta-analysis of 16 randomized controlled trials (RCT’s) by Sgourakis  
(51), they compared median survival of patients undergoing primary stenting 
versus patients undergoing other loco-regional treatment modalities including 
brachytherapy and radiation therapy.  Their results suggest a shorter median 
survival at one year in the stent group, however a higher re-intervention rate in the 
group undergoing other loco-regional treatment (these include laser, thermal 
ablation, radiation therapy and argon plasma coagulation). 
Zhang   (74) from China suggested in  an editorial in The Lancet that patients with 
short survival expectancy (3 years) should be initially treated with stenting, due to 
its initial rapid relief of dysphagia, and then possibly followed by brachytherapy. 
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It would then seem that the ideal management of these patients would be the 
combination of stenting for the initial superior relief of dysphagia, followed by 
brachytherapy.  
In another study from China, Guo  (75) compared SEMS to 125I coated SEMS 
with primary outcomes being dysphagia relief and survival time.  Their dysphagia 
scores were similar at 1 month in both groups, however after 1 month dysphagia 
scores were better in the 125I coated SEMS group.  Median survival time was 7 
months in the  125I coated SEMS group compared to 4 months in the SEMS group.  
These results were statistically significant. 
Health economic costs between stenting and brachytherapy were evaluated.  
Stenting was cheaper than brachytherapy overall, due to the longer hospital 
stay in the brachytherapy in a study from Sweden  (73), and in another study 
carried out in the Netherlands stenting and brachytherapy costs were similar  
(8).  It has to be noted however that the Swedish study 3 fractions of 
brachytherapy were given compared to a single-dose in the Dutch study. 
Table III summarizes the randomized trials used in the literature review. 
 
1.4.2.5. Chemotherapy 
 
Chemotherapy or combined chemoradiotherapy has been described for the 
palliative management of malignant dysphagia, however comparative studies 
are few.   
In a prospective cohort study  (76) evaluating primarily the dysphagia relief 
in patients with advanced disease, the authors described CRT as effective in 
the management of malignant dysphagia.   
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They reported 78% of patients as having improved swallowing, and 41% of 
patients returning to normal swallowing.  14% of patients had no 
improvement in the dysphagia score.  The mean survival in these patients 
was 7 months and tolerance to the treatment was acceptable.  These patients 
received 35 Gy in 15 fractions of RT with one cycle of cisplatin and 5-
fluorouracil. 
These findings were similar in another study by Harney et al (77). 
In a comparative study by Wong  (78), the author’s retrospectively compared 
CRT to stenting as palliative therapy in malignant dysphagia.  There were 36 
patients in each group.  The dysphagia scores were similar after treatment 
and 8 patients in the CRT group need re-intervention by stenting at a median 
4.5 months.  Median survival was also longer in the CRT group at 10.8 months 
compared to 4 months in the stent group.  Of note is CRT therapy consisted of 
cisplatin and 5-fluorouracil infusions, with concurrent radiotherapy of 50 to 
60 Gy in 25 to 30 fractions over a period of 5 to 6 weeks. 
Chemotherapy alone  (79) may be considered for palliative treatment in 
patients that are medically fit enough.  Dysphagia should be relieved before 
chemotherapy is commenced.  The disadvantage of stent placement is the 
risk of migration into the stomach after chemotherapy and subsequent tumor 
shrinkage. 
It should be noted that Sur  (80) looked at 200 patients that received either 
brachytherapy alone or were first chemosensitized with 5-FU then followed 
by brachytherapy.  He reported an increased rate of stricture formation due 
to fibrosis with the need for dilatation.   
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This occurred possibly because chemotherapy induces more mucosal 
damage, which is then potentiated by brachytherapy followed by fibrotic 
healing causing strictures.  The dysphagia-free median survival times were 
similar between the 2 groups after 6 months, but after 1 year they were 
better in the group that did not receive prior chemotherapy. 
Nevertheless, CRT has shown promising results with regard to median 
survival, and should be considered if patients are fit enough to undergo 
treatment. 
   
1.4.2.6. The role of surgery 
 
Surgery has little role to play in the palliative treatment of patients with 
oesophageal cancer.  In the presence of advanced disease transtumoral 
resections are associated with poor survival rate and should be avoided as 
much as possible  (81). 
In a comparative retrospective study between surgery and other treatment 
modalities (chemotherapy, RT or both) in patients with T4 disease, the 
results show no survival benefit in the surgery group  (82). 
Palliative oesophagectomy can be considered for specific patients who 
develop resectable disease after CRT, without the presence of distant 
metastasis  (83). 
Bypass surgery has now largely been replaced by other more effective 
methods of palliation.  Gastostomy feeding tubes have some role to play in 
palliation when other means of dysphagia relief have failed. 
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1.4.2.7. Fistula management 
 
Fistulas can be formed most commonly between the oesophagus and the 
respiratory tract due to advanced disease, or due to complications of laser 
therapy, RT or stent placement  (79).  Patients usually present with coughing 
after drinking or eating, dyspnoea and recurrent chest infections.  The 
mainstay of treatment is the placement of covered SEMS to occlude the 
fistula, with no clear differences between the different covered metallic 
stents available  (84). 
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Table III:  Summary of Randomized Trials 
Study 
 
Group  N Histology Tumor site 
(oesophagus) 
Dysphagia  
Relief 
Median  
Survival 
Cost/pt HRQL Complications  
(number of patients) AC ESCC 
Bergquist  
et al  (33) 
Stent  
Brachy (7Gy x 3) 
34 
31 
13 
13 
15 
11 
* Superior at 1/12 
Superior after 1/12 
149 days 
157 days 
* 
 
 
Better overall 
TOF (2), Bleeding (2) 
TOF (1),       
Perforations (2) 
Sur et al  
(69) 
Brachy (16Gy x2) 
Brachy (18Gyx3) 
118 
104 
- 
- 
118 
104 
Majority 
Middle 1/3 
No difference 
No difference 
207 days 
273 days 
- 
- 
- 
- 
Stricture (12), TOF (11) 
Stricture (13), TOF (12) 
 
Homs et al  
(6) 
Stent  
Brachy (12Gy single) 
108 
101 
68% 
69% 
29% 
27% 
Middle1/3, 
Lower 1/3 
Superior at 1/12 
Superior after 1/12 
145 days 
155 days 
8215€ 
8135€ 
Brachy more stable 
long term 
TOF (3),       Perforations (2) 
TOF (2),  Perforations (1) 
Wenger et 
al (73) 
Stent 
Brachy 
28 
24 
13 
17 
13 
16 
Mainly middle 
and distal 1/3 
Superior at 1/12 
Superior 2/12-3/12 
(equal after that) 
158 
162 
24564€** 
35414€** 
*  
De Palma et 
al (38) 
Plastic stent 
Metal stent 
20 
19 
* * * Grade 3 to 1 
Grade 2.9 to 0.5 
6.2 months 
6.6 months 
* * Perforations (3), Bleeding (1) 
Perforations (0), Bleeding (0) 
 
O’Donnell 
et al (41) 
Plastic stent 
Metal stent 
25 
25 
14 
12 
10 
13 
Middle 
oesophagus 
Equal at 1/12 
Superior at 2/12 
62 days 
107days 
* Superior with metal 
stent 
Re-interventions (8); Failed placement 
(2); Re-interventions (10) 
 
Vakil et al 
(46) 
Covered stent  
 
Uncovered  
32 
 
30 
27 
 
25 
* Gastro-
oesophageal 
junction 
Grade 3 to 1 at 1/12 
 
Grade 3 to 1 at 1/12 
Equal  
 
Equal 
* * Tumour ingrowth (1);  Stent 
migration(4) 
Tumour ingrowth (9) ; Stent 
migration(1). 
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Table III:  Summary of Randomized Trials (cont.) 
Study 
 
Group  N Histology Tumor site 
(oesophagus) 
Dysphagia  
Relief 
Median  
Survival 
Cost/pt HRQL Complications  
(number of patients) 
AC ESCC 
Siersema et 
al (48) 
Ultraflex stent 
 
Flamingo wall stent 
 
Gianturco-Z stent 
 
34 
 
33 
 
33 
 
21 
 
21 
 
25 
13 
 
11 
 
7 
 
Middle, distal 
oesophagus and 
cardia 
Grade 3.3 to 0.5 
 
Grade 3.2 t0 0.5 
 
Grade 3.2 to 0.7 
104 days 
 
113 days 
 
110 days 
* * Major complications (8); Recurrent 
dysphagia(9) 
Major complications (6); Recurrent 
dysphagia(9) 
Major complications(12); Recurrent 
dysphagia(5) 
Sabharwal 
et al (47) 
Flamingo Wallstent 
 
Ultraflex stent 
22 
 
32 
* * Lower 1/3,  
Gastro-
oesophageal 
junction 
Grade 2. 9 to 0.9 
 
Grade 2.7 to 1 
4 deaths at 
30 days 
5 deaths at 
30 days 
* * Migration (1); Severe reflux (1) 
 
Migration (2); Severe reflux (2) 
Wenger et 
al (49) 
Dua anti-reflux stent 
 
Z-stent  
19 
 
22 
13 
 
18 
4 
 
4 
 
Oesophagus 
(61%) and cardia 
(39%) 
Similar improvement 
in both groups 
58 days 
 
68 days 
* Equal symptoms of 
reflux, 
Dyspnoea symptoms 
improved in anti-reflux 
stent group 
Perforation (0); Severe reflux (2) 
 
Perforation (2); Severe reflux (2) 
Homs et al 
(50) 
Anti-reflux stent  
 
Standard stent 
15 
 
15 
12 
 
12 
3 
 
3 
 
Distal 
oesophagus/ 
cardia (80/20%) 
Grade 3 to 1 at 2/52 
 
Grade 3 to 0 at 2/52 
107 days 
 
 87 days 
* 3 patients complained of 
reflux 
2 patients complained of 
reflux 
23% increased acid levels on 24-hor pH 
monitoring 
10% increased acid level on 24-hour pH 
monitoring 
Lightdale et 
al (52) 
PDT
 
 
Nd: YAG 
118 
 
118 
52% 
 
50% 
48% 
 
50% 
 
Upper, middle 
and lower 1/3  
 
Equal relief at 1/12 
 
Equal relief at 1/12  
123 days 
 
140 days 
* * Sunburn (19%); Perforations (1%) ; 
Termination: serious adverse events 
(3%)  
Sunburn (0%); Perforation (7%); 
Termination: serious adverse events 
(19%) 
Spencer et 
al (57) 
 
Nd:YAG
 
 
Nd:YAG + 
Brachytherapy
 
11 11 
 
11 
0 
 
0 
Distal 1/3 and  
cardia 
Dysphagia palliation 
of 5/52 
Dysphagia palliation 
of 19/52 
80 days 
 
104 days 
* * Re-interventions (5) 
 
Re-interventions (2) 
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Table III:  Summary of Randomized Trials (cont..) 
Study 
 
Group  N Histology Tumor site 
(oesophagus) 
Dysphagia  
Relief 
Median  
Survival 
Cost/pt HRQL Complications  
(number of patients) 
AC ESCC 
Dallal et al 
(59) 
Thermal tumor 
ablation  
 
Stent  
34 
 
31 
23 
 
19 
10 
 
10 
* Median change in 
dysphagia score at 1/12 
was 0 
Median change in 
dysphagia score at 1/12 
was 0 
125 
 
68 
6235 £ 
 
3378 £ 
Overall better 
 
Overall worse 
 
Perforations (2); TOF (3); Recurrent 
dysphagia(7) 
 
Perforations (0); TOF (0); Recurrent 
dysphagia(4) 
Adam et al 
(60) 
Laser 
 
Stent uncovered 
 
Stent covered  
18 
 
19 
 
23 
13 
 
12 
 
15 
4 
 
6 
 
6 
Middle and upper 
1/3: 6; Lower 1/3: 
12 
Middle and upper 
1/3: 10; Lower 
1/3: 9 
Middle and upper 
1/3: 9; Lower 1/3: 
14 
2 (grade of dysphagia 
after treatment) 
 
1 (grade of dysphagia 
after treatment) 
1 (grade of dysphagia 
after treatment) 
56 
 
60 
 
48 
* * Re-intervention (100%) 
 
Re-intervention (26%) 
 
Re-intervention (43%) 
Harvey et al 
(76) 
Chemo-radiotherapy 106 51 50 Upper 1/3: 12 
 
Middle 1/3: 30 
Lower 1/3:  64 
 
49%:  grade 0 dysphagia 
after treatment 
78%: at least 1 grade 
improvement 
14%:  no improvement 
7 months * * Treatment- related deaths:  6 (7%) 
* Not stated,  ** Total lifetime costs per patient,  PDT (photodynamic therapy),  Nd:YAG (neodynium ytrium aluminium garnet laser), TOF (trache-oesophageal fistula) 
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2. AIM OF STUDY 
 
The aim of the retrospective study was to compare RT (EBRT or brachytherapy) 
versus stenting for the palliative treatment of advanced oesophageal cancer with 
malignant dysphagia in the South African context.  
The primary outcomes included: 
• Hospital stay (in number of days) 
• Number of hospital admissions 
• Number of days from day first seen to either stenting or RT 
• The determining of hazard ratio (mortality risk) for patients residing 
further than 130 km from a secondary hospital 
Secondary outcomes included:  
• Number of days from intervention to biopsy 
• Procedure related complications 
• Median survival in both groups 
 
 
 
 
 
 
 
 
 
 43
3. PATIENTS AND METHODS 
 
3.1. Patients 
 
Between February 2005 and January 2008 the records of a total of 66 
patients who presented with dysphagia grade III-IV (Table II) were 
evaluated. Of the 66 patients, 30 were included in the study of which 18 
patients made up the stent group and 12 patients the RT group.   
Inclusion criteria included all patients that presented with malignant 
dysphagia and where inoperable oesphageal cancer was diagnosed.  
Patients who received combined treatment (i.e. Stent and brachytherapy) 
or feeding gastrostomies as palliation therapy were excluded from the 
study. 
 
3.2. Methodology 
 
Tshepong Hospital is a secondary hospital that drains a large portion of 
the population in the North-West Province.  Although the hospital 
facilities include a surgical department that offers oesophageal stenting 
under screening, it does not offer radiation therapy. Imaging facilities 
include computer tomography (CT) scanning, ultrasound (US) evaluation 
and barium swallow.  
Patients were evaluated with standard laboratory investigations, which 
included a full blood count, urea and electrolytes, liver function tests and 
calcium, magnesium and phosphate levels.   
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Radiological investigations included a chest X-ray, abdominal US, barium 
swallow and CT scan. Patients with severely poor general health and 
deemed not fit for any surgery did not undergo a CT scan and were 
assumed to have metastatic disease.  
Patients either underwent stenting or RT.  Due to the prolonged delays in 
patients receiving RT, stenting was introduced in the unit. At the time 
stenting was introduced, all patients with malignant dysphagia were 
subsequently stented according to unit policy.  
All patients in the RT group were initially sent to an academic hospital for 
brachytherapy. The decision to give external beam RT was made by the 
radiation oncologists if the lumen of the oesophagus was too narrow for 
brachytherapy.  Patients were dilated where required by the surgical 
department at Tshepong Hospital, however this was not adequate in some 
instances.   
After treatment dysphagia was assessed clinically (see table II) after 2 
weeks, and then monthly.   Median survival was determined in both 
groups.  In patients that were lost to follow-up, the death certificates were 
retrieved from the central department of home affairs to determine the 
date and cause of death. 
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3.3. Procedures 
 
Before stenting or RT, all strictures were dilated to at least 12 mm with a 
Savary dilator over a guidewire.  Gastroscopy with dilatation and stent 
placement was done under general anaesthesia (hospital policy). 
Eighteen patients were stented with a self-expandable, coated, metallic 
stent (Ultraflex esophageal covered stents, Boston Scientific, Natrick, MA, 
USA) under fluoroscopic guidance.   
Of the 12 patients who received RT, 5 received brachytherapy and 7 
received external beam RT.   
Patients undergoing RT either received brachytherapy or external beam 
RT (EBRT).  EBRT was chosen if brachytherapy was unsuccessful due to 
advanced stenosis of the oesophagus. 
 
3.4. Data Analysis 
 
Patient records and surgical records were analysed.  Patients that were 
still alive (37%) were followed up at the outpatients department.   
Results were tabulated and statistically analysed using the Kruskal-
Wallis test with a 95 % confidence interval, and p<0.05 was regarded as 
statistically significant.  Median survival was determined using Kaplan-
Meier estimates and the log-rank test. 
The hazard ratio of patients living further than 130 km from a secondary 
hospital was determined using Cox regression analysis adjusted to 
treatment. 
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3.5. Ethics approval 
 
Ethical approval was obtained from the Human Research Ethics 
Committee (M071109) in February 2008 (Appendix C).   
No consent was required from patients and the data was coded and 
remained anonymous. 
 
 
 
4. RESULTS 
 
Of the 66 patients evaluated during the study period, 33 patients did not fulfill 
the criteria to be included in the study, as they did not receive any palliative 
therapy (i.e. stent insertion or RT).  Reasons included lost to follow-up (n=10), 
death awaiting treatment (n=9), gastrostomy tube was inserted (n=3), refusal 
of hospital treatment (n=1), other malignancies causing dysphagia (n=3), 
benign oesophageal strictures (n=4) and inflammatory/infective causes of 
dysphagia (n=3). 
Of the remaining 33 patients, 3 patients received both RT and stent insertion, 
and were therefore also excluded from the study. 
The 30 remaining patients included in the study comprised of 21 males and 9 
females.  Median age was 64 in the stent group and 72 in the RT group (Table 
III). 
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All patients were black Africans.  Only 14 of the patients had contact details, 
and most patients were referred from peripheral hospitals.  All patients were 
inoperable at time of presentation due to advanced disease and/or were in 
poor general health.  Patients presented with dysphagia grade III-IV (Table 2).  
The degree of dysphagia on presentation could not be ascertained in 2 of the 
stented patients.  Most patients presented with middle third tumors.  In the 
stent group 10 patients presented with middle third, 5 patients presented 
with distal third and 2 patients presented with upper third oesophageal 
tumours. In one patient the tumour site could not be determined. 
In the RT group 8 patients presented with middle third, 2 patients presented 
with distal third and 1 patient presented with upper third oesophageal 
tumours. In 1 patient the tumour site could not be determined. 
All patients included in the study had a poor nutritional status ascertained 
clinically (wasted), and with a history of excessive weight loss.  One patient in 
the stent group was known with HIV and pulmonary tuberculosis.  ECOG or 
Karnofsky perfomance scores were not determined in the study patients.   
Histology examination revealed squamous cell carcinoma in all the patients.   
 In 9 cases stenting was done at initial gastroscopy on the clinical basis of 
malignancy of the oesophagus; the remaining 9 patients were stented 
following histological confirmation of the disease.  There was a bias toward 
the stenting group as these patients were stented within 8 days of 
presentation to hospital on clinical grounds of carcinoma, thereby avoiding 
the delay of histological confirmation and hence decreasing the number of 
days from intervention to management in the group.  Cancer was confirmed 
 48
histologically after stenting.  The remaining patients from both groups were 
treated only once cancer was confirmed histologically. 
In the RT group the patients needed to be sent to an academic hospital where 
this service was available (a distance of >120 km away).  On arrival at the 
academic institution, patients would receive an appointment to have RT in 1 
to 2 weeks time, after which they were sent back to their referring hospital.  
The median number of admissions was 2 in the stent and 3 in the RT groups.  
This difference between the two groups was mainly due to the need for 
repeated cycles of EBRT.  Hospital stay and time from first seen to treatment 
was also significantly shorter in the stent group.   
Biopsy was done within 3 days of first presentation in 69% of the patients 
(n=20).  The median number of days from presentation to biopsy did not 
differ between the two groups. 
Outcomes are depicted in table IV. 
 
 
 
 
 
 49
 
Table IV:  Comparison of outcomes between the patients receiving 
palliative treatment with stenting and those receiving radiotherapy 
 
 
 
Variables Stent  group 
(n=18) 
Median (Range) 
Radiotherapy 
group 
(n=12) 
Median (Range) 
*p- value 
Gender 
Females 
Males 
 
5 
12 
 
2 
10 
 
 
Age 64 (39-85) 72 (45-81) 
 
p= 0.21 
 
Number of 
admissions† 
2 (1-4) 3 (2-7) p=0.0180 
Hospital stay† 15 (1-89) 29 (11-63) p=0.0072 
Days to 
procedure† 
6 (0-104) 49 (35-377) p= 0.0108 
Days to biopsy 
 
2 (0-43) 2 (1-19) p=0.71 
*A p-value of <0.05 is statistically significant 
†Primary outcomes 
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A number of patients in both groups had excessively high values for various 
outcomes (number of admissions, hospital stay and time to intervention), which 
caused considerable delays in treatment.  These delays were mainly caused by 
repeated cycles of EBRT, administrative and logistic delays, defaulted treatment 
by patients and technical factors, which include faulty gastroscope and EBRT 
machine.   
Table V lists the causes for excessive hospital duration, admissions and time to 
intervention in 18 patients in both the stent and RT group.  Delays were seen in 
both groups.  In the RT group the main causes of delay were repeat cycles of RT 
and defaulted treatment.  Due to multiple admissions required for RT, and long 
distances to be travelled especially in patients from rural areas, the risk of 
defaulted treatment was higher. 
Four patients in the RT group re-obstructed after treatment, 3 patients who 
received brachytherapy and 1 patient who received EBRT.  Two patients 
obstructed within 3 months and 2 patients obstructed within 4 months. 
Three patients in the stent group re-obstructed due to tumour over-growth.  One 
patient obstructed within 2 months and 2 patients obstructed within 4 months. 
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Table V:  Upper range values of 18 patients in different outcomes with causes in 
both groups 
OUTCOME GROUP PATIENT UPPER RANGE VALUES 
IN PATIENTS 
CAUSES 
 Admissions Stent 1 
 
2 
Number of admissions 3:   
 
Number of admissions 4:   
Dehydration and lung 
abscess 
Technical factors 
RT 3 
4 
5 
Number of admissions 5:   
Number of admissions 6:   
Number of admissions 7:   
Repeated cycles of EBRT 
Repeated cycles of EBRT 
Repeated cycles of EBRT 
Hospital Stay 
(days) 
Stent 6 
 
 
7 
 
8 
 
89 days: 
 
 
36 days: 
 
34 days: 
 
Awaiting faulty EBRT 
machine, developed TOF, 
stented 
Dehydration and lung 
abscess 
Treatment for dehydration 
and lung abscess 
RT 9 
10 
63 days: 
58 days: 
Repeated cycles of EBRT 
Transport problems 
Time to 
Intervention 
(days) 
Stent 11 
 
12 
 
13 
14 
 
15 
104 days: 
 
 
86 days: 
 
70 days: 
62 days: 
 
57 days: 
Administrative delays 
awaiting brachytherapy, 
therefore stented 
Repeat biopsy, histology 
results delay 
Defaulted treatment 
Repeat biopsy, histology 
results deay 
Defaulted treatment  
RT 16 
17 
18 
377 days: 
131 days: 
98 days: 
Defaulted treatment 
Defaulted treatment 
Defaulted treatment 
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The median survival of patients in both groups was 129 days from the date first 
seen to death, survival ranging from 14 to 407 days. One patient was still alive at 
the time of writing, and the records of 4 patients could not be found; they were 
presumed to have died (Fig. 1). The median survival curves comparing the RT 
group with the stent group are depicted in Fig. 2. 
The hazard ratio for living a distance >130 km from a secondary hospital 
adjusted to treatment was 1.34 (p=0.497). The distance curve shows an increase 
in risk of death at a distance of >130 km from a secondary hospital, however this 
did not reach statistical significance (Fig. 3). 
7 patients in the RT and 6 patients in the stent group lived at a distance further 
than 130 km from the secondary hospital.   
5 patients in the RT defaulted treatment, which caused considerable delays in 
management.  1 patient in the RT group died in hospital due to advanced disease 
after treatment and another patient in the RT group needed repeated cycles of 
RT resulting in multiple admissions and delays to treatment. 
In the stent group there was delay to treatment in 1 patient due to no stock of 
stents.  In the remaining patients in the stent group living further than 130 km 
from a secondary hospital there were no delays to treatment.  
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Figure 1.  Survival curve of all patients in both groups.  The x-axis depicts 
the number of days and the y-axis depicts the proportion of patients that 
have survived. 
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Figure 2.  Median survival curves between the stent and radiotherapy 
groups.  The x-axis depicts the number of days and the y-axis depicts the 
proportion of patients that survived. 
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Figure 3.  Survival curves between patients that reside >130 km and 
patients that reside<130 km to a secondary hospital.  There is a survival 
advantage in patients that reside <130 km from a secondary hospital, this 
difference did not reach statistical significance. 
 
 
 
 
 
 
 
Procedure related complications were noted in 4 patients in the stent group: 
stent migration (n=1); stent overgrowth (n=1); failure of stent to deploy 
completely (n=1); and death in theatre during stenting (n=1).  
There were no major complications reported in the RT group. 
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5. DISCUSSION 
 
Many studies have been done comparing stenting to RT in the palliative 
treatment of esophageal cancer.  Many of these studies have been done in a first 
world setting and are therefore not subject to many of the socio-economic 
constraints present in the developing world.  Many advances have been made 
with regards to palliation of malignant dysphagia and most commonly used 
methods include stent insertion and brachytherapy.  
With all these advancements in treatment, our patients nevertheless present late 
and/or are faced with other socio-economic constraints and may not benefit 
from the longer lasting effect of brachytherapy alone or in combination with 
chemotherapy. 
There was a significant increase in hospital stay, number of days from first seen 
to intervention and number of admissions in the group of patients who received 
RT. This was attributable to a number of factors.  The majority of patients were 
referred from smaller peripheral hospitals to Tshepong Hospital.  After 
admission, gastroscopy and biopsy was performed.  Patients were then 
discharged and a follow up date given for histology results.   
 
After confirmation of malignancy on histology they were then referred to an 
academic institution for brachytherapy or external beam RT.   
Due to the high patient volume in these centers, patients were given an 
appointment for treatment, usually in 1 to 2 weeks time, and returned to 
Tshepong Hospital with an appointment date.   
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The fact that most patients were from distant rural areas, meant that transport 
problems were a significant factor in delaying treatment.  The fact that they 
needed more than 1 session of RT also exacerbated the situation.  Furthermore, 
Sur  (69) described that the most effective course of brachytherapy was 
delivered in 2 or 3 fractions which would mean further admissions to hospital, 
longer hospital stays and an increased risk of default for patients. 
Administrative problems including patients being referred with no results or 
incorrect results, was also a reason for delay and increased hospital stay. 
 
Patients in both groups defaulted treatment and were lost to follow-up, however 
in the stenting group the patients were either stented on initial presentation or 
after histological confirmation of malignancy with a decreased number of 
admissions and therefore less chance of defaulting treatment due to socio-
economic reasons.  
Patients that were stented immediately had a dramatic decrease in hospital stay 
and had immediate relief from dysphagia.  
Our study focuses on the short median survival of patients with end-stage 
esophageal cancer and it has been shown previously that patients receiving 
brachytherapy or stenting have a median survival of 120 days (33).  
Median survival times in our study were 140 days in the RT group and 105 days 
in the stent group (Fig. 2), although patients in both groups presented with 
equally advanced local disease and high-grade dysphagia.  One patient in the 
stenting group was known with HIV and pulmonary tuberculosis, which could 
have impacted on the median survival of the group.   
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The combined median survival time of both the stenting and radiotherapy 
groups was 129 days (Fig 1).  
 
Although health-related quality of life scores are more stable in patients 
receiving brachytherapy  (33,72), our study emphasizes on delays in receiving 
brachytherapy as palliative treatment.  From the results it can be seen that the 
median number of days to intervention in the RT group was 49 compared to 6 
days in the stenting group.   Quality of life is the mainstay of palliative treatment 
in patients with end-stage cancer irrespective of the median survival.  Invariably 
less time to treatment is required for stenting.   
Therefore despite the median survival being better in the RT group, these 
patients were delayed in treatment and invariably had a shorter quality of life 
and dysphagia-free survival. 
There was no significant difference in the number of days from presentation to 
time of biopsy.  This is important as it indicates that there was no bias to either 
group with regards to initial work-up, in other words the significant difference in 
time to intervention between RT and stenting is the delay from initial work-up to 
final management. 
A prognostic model published from the results of the SIREC trial shows that 
patients with a poor prognosis fare better with stenting than brachytherapy with 
regards to median survival and dysphagia-adjusted   survival    (85). 
They describe male gender, age more than 70, tumour length of more than 10 
cm, presence of distant metastases and a worse WHO performance score as poor 
prognostic factors.   The majority of the patients in our study were males, above 
the age of 70 and had distant metastases on presentation.   
 59
Unfortunately the tumour length and performance scores were not documented.  
Furthermore in a study by Berquist  (86) in 2011 they described the importance 
of HRQL questionnaires as important predictors of outcome in these types of 
patients.  These HRQL questionnaires and determining of perfomance scores 
should become standard in all hospitals across the country when managing 
patients that present with oesophageal cancer.  
In addition, the distance a patient resides from a secondary hospital is an 
important factor when assessing these patients. A distance of 130 km was 
chosen, as most of the rural areas were an average of 130 km away from a 
secondary hospital.  The hazard ratio in these patients living further than 130km 
was 1.34.  A criticism of the latter is the small sample size and values did not 
reach statistical significance, however it did have clinical significance and 
distance should always be considered when managing these patients.    
Patients especially from distant rural areas have more of a chance of delay in 
treatment due to a lack of an efficient transport system and therefore might not 
be able to follow-up for further treatment.   
An adequate history should be taken to determine whether transport to hospital 
and therefore follow-up might become an issue. 
When distances are long, patients tend to fall in the poor prognosis group. 
In these cases it might be more appropriate to stent these patients. 
 Patients with moderate or good prognosis can then be treated with single-dose 
brachytherapy and benefit from the long-term dysphagia-free effect of this 
treatment.   
Efforts could also be focused on efficiently alleviating many of the socio-
economic hurdles described, specifically aimed at time from first seen to RT.   
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Ideally patients with a poor prognosis should be admitted to hospital, a biopsy 
taken on initial presentation and kept in hospital until the biopsy results confirm 
malignancy – after this the patient should be stented.  This avoids prolonged 
hospital stay and decreases the likelihood of defaulting treatment because of 
socio-economic constraints, which in many cases are currently unavoidable.  
Four of the 12 patients in the RT group re-obstructed within 4 months. These 
patients were then dilated to relieve the obstruction.   A better option for these 
patients would be stenting over serial dilatations.   
Furthermore, with a nationwide effort in an attempt to overcome the socio-
economic constraints that affect the delivering of adequate treatment to our 
patients, another option in the management of these advanced patients from 
rural areas is the combination of single-dose brachytherapy and stenting, adding 
a prolonged dysphagia-free survival to these patients.  
 
6. CONCLUSIONS AND RECOMMENDATIONS 
 
A comparative study between oesophageal stent insertion and RT for the 
palliative treatment of patients with advanced oesophageal cancer in a 
peripheral South African Hospital showed the following: 
• Patients presenting with malignant dysphagia have a limited lifespan 
and focus should be on improving their quality of life. 
• Patients undergoing RT have a significantly longer hospital stay and 
longer wait to treatment. 
• Any unnecessary increases in hospital stay impacts negatively on 
quality of life. 
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• With socio-economic constraints imposed upon the health sectors of 
the developing world, we conclude that stenting is a feasible option in 
this situation. 
• We have adopted this treatment because it is easier and more 
convenient for rural patients with a limited lifespan. 
• Major problems seem to be associated with giving these patients RT at 
secondary hospitals.  
• Either this situation must be improved, or stenting should become the 
preferred treatment. 
 
Recommendations are as follows: 
• Units treating patients with inoperable oesophageal cancer should 
audit their results before determining the optimum treatment for 
these patients. 
• There should be close collaboration between all departments that 
are managing these patients and between hospitals.  This will 
allow any effective overcoming of any hurdles that are faced 
during the management of patients. 
• Brachytherapy and EBRT may be introduced to a number of 
secondary hospitals, which will take off some of the burden faced 
at major academic centers, if this is feasible. 
•  Possibly an introduction of a taskforce that specifically looks into 
the administrative and logistic constraints faced when managing 
these patients.  This could identify more closely the problems that 
need to be addressed effectively and efficiently. 
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7. LIMITATIONS OF THE STUDY 
 
Due to the retrospective nature of the study, important information regarding 
tumour and patient characteristics could not be determined.  Tumour 
characteristics include tumour length, axial deviation and radial extension.  
Patient characteristics include ECOG and Karnofsky perfomance status 
scores. All these factors play an important role in determining overall 
prognosis in these patients.   
Without complete data information an unbiased comparison between 
stenting and RT is not entirely possible.  However, the aim of the study was 
mainly to compare the path to treatment and the constraints faced by our 
patients rather than the efficacy of these treatments in an ideal setting.  
Although a prospective study would have been more accurate, the study 
revealed a problem that exists in the management of these patients.  Efforts 
should now be made on alleviating the problems.  Furthermore due to the 
small sample size, statistics did not reach statistical significance and are 
prone to type II error. 
Nevertheless, the numbers show a trend that clinically have an impact and 
cannot be ignored. 
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